PAB 0.00% 0.3¢ patrys limited

Ann: PAT-DX1 Crosses Blood Brain Barrier to Reduce Tumour Size, page-86

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,619 Posts.
    lightbulb Created with Sketch. 587
    Check out this scientific paper.

    Not sure if it’s the same 3e10 patry’s is Using, but it does seem to be quite similar in name and mechanism of action.

    http://mct.aacrjournals.org/content/molcanther/early/2012/10/01/1535-7163.MCT-12-0476-T.full.pdf

    These scientists also made quite a bold statement about the significance of this type drug in cancer therapy in their abstract,

    “The use of cell-penetrating bispecific antibodies in targeted molecular therapy will significantly broaden the spectrum of accessible intracellular targets and may have a profound impact in cancer therapy. Mol Cancer Ther; 11(10); 1– 5. !2012 AACR.“
 
watchlist Created with Sketch. Add PAB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.